Chelsea Therapeutics Provides an Update on Northera(TM) (droxidopa) Regulatory Status and Development Program
03. Juli 2012 06:45 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., July 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a written response from the U.S. Food and Drug Administration (FDA) to Chelsea's...
Combined Northera(TM) (droxidopa) Data From Two Phase 3 Trials Confirm Symptom Improvement in Patients With Neurogenic OH
21. Juni 2012 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 21, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced results from an integrated dataset of two phase 3 studies, Study 301 and Study...
Chelsea Therapeutics Announces $6 Million in Cost Saving Initiatives to Support Expanded Enrollment Initiatives for Northera Study and Extend Cash Runway Into Third Quarter 2013
07. Juni 2012 16:16 ET
|
Chelsea Therapeutics
Officers and Directors Agree to 25% Reduction in Compensation
Approximately 35% of Remaining Employees to Transition to Part-Time Status
Chelsea Eliminating All Performance Bonuses Until...
Chelsea Therapeutics Reports Top-Line Results of Phase II Trial of CH-4051 in Rheumatoid Arthritis
31. Mai 2012 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., May 31, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that a preliminary analysis of its dose-ranging exploratory Phase II trial of...
Chelsea Therapeutics Completes End-of-Review Meeting With FDA for Northera(TM) (droxidopa) Capsules New Drug Application
22. Mai 2012 07:00 ET
|
Chelsea Therapeutics
Chelsea Proposing to Change Primary Endpoint and Submit Dizziness Data From Ongoing Study 306B to Support Resubmission of Northera NDA for the Treatment of Symptomatic Neurogenic Orthostatic...
CORRECTING and REPLACING -- Chelsea Therapeutics Reports First Quarter 2012 Results
01. Mai 2012 16:46 ET
|
Chelsea Therapeutics
In a press release issued earlier today by Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), please note the last sentence of the sixth paragraph should have read: Chelsea anticipates that...
Chelsea Therapeutics Reports First Quarter 2012 Results
01. Mai 2012 16:15 ET
|
Chelsea Therapeutics
Chelsea To Meet with FDA in May to Discuss Next Steps for Northera New Drug Application
Postponing Conference Call Until Following FDA Meeting
CHARLOTTE, N.C., May 1, 2012 (GLOBE...
Results From Chelsea Therapeutics' Pivotal Northera(TM) (Droxidopa) Study to be Presented at the American Academy of Neurology's Annual Meeting
27. April 2012 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 27, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Horacio Kaufmann, M.D., Professor of Medicine, NYU Langone Medical...
Chelsea Therapeutics is a Proud Sponsor of the Parkinson's Unity Walk
25. April 2012 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 25, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today it is proud to serve as a platinum corporate sponsor of the Parkinson's Unity...
Chelsea Therapeutics to Present at the 19th Annual Future Leaders in the Biotech Industry Conference
20. April 2012 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 20, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 19th Annual Future Leaders in the Biotech Industry Conference...